Trust Signals
Written by the FormBlends Medical Team. Reviewed against primary human clinical literature. No affiliate links influence compound selection. All efficacy claims are graded by evidence type. Last updated: May 29, 2026.Key Takeaways
- Hexarelin produces a larger absolute GH pulse than ipamorelin at equivalent molar doses in human studies, but co-stimulates cortisol and ACTH, which ipamorelin largely does not.
- Ipamorelin is the more selective GHSR-1a agonist of the two; it avoids meaningful prolactin and cortisol elevation at doses studied, making it the lower-hormonal-spillover option.
- Hexarelin shows measurable receptor desensitization with repeated daily dosing within days to weeks; intermittent dosing protocols exist specifically to mitigate this.
- Neither peptide is FDA-approved; both are WADA-prohibited; human RCT data for ipamorelin specifically are sparse compared to hexarelin.
- Reconstituted solutions of both degrade through hydrolysis and oxidation; refrigerated storage at 2 to 8 degrees Celsius is required post-reconstitution.
Direct Answer: Hexarelin vs Ipamorelin in 50 Words
Hexarelin is the more potent GH secretagogue but raises cortisol and prolactin as documented side effects. Ipamorelin releases less GH per dose but is receptor-selective, avoiding cortisol and prolactin spillover. For most research protocols prioritizing hormonal cleanliness over raw pulse size, ipamorelin is the preferred starting compound.- What are hexarelin and ipamorelin pharmacologically?
- Evidence ledger: what the data actually show
- How do they stimulate GH release, with specific numbers?
- What are the real side-effect differences?
- Does hexarelin cause faster receptor desensitization?
- What most comparison pages get wrong
- Honest head-to-head comparison table
- Dosing and operational label literacy
- Stability and formulation gotchas
- FAQ
- Sources
What Are Hexarelin and Ipamorelin Pharmacologically?
Both hexarelin and ipamorelin are synthetic growth hormone secretagogues (GHS) that act as agonists at the ghrelin receptor, formally GHSR-1a (growth hormone secretagogue receptor type 1a). They mimic the GH-releasing action of ghrelin but were engineered to be more stable and potent than the endogenous ligand.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Hexarelin (His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2) is a six-amino-acid peptide developed in the early 1990s. It has a higher binding affinity at GHSR-1a than ipamorelin and also interacts with CD36 scavenger receptor, a binding site relevant to cardiovascular and adipose tissue effects studied separately from its GH axis activity.
Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) is a five-amino-acid peptide. Its defining characteristic in early preclinical work by Raun et al. (1998, European Journal of Endocrinology) was high selectivity: it released GH in rats without the prolactin, ACTH, or cortisol stimulation seen with earlier secretagogues including GHRP-6 and, to a lesser extent, hexarelin.
Evidence Ledger: What the Data Actually Show
| Claim | Best evidence type | Effect direction | Confidence |
|---|---|---|---|
| Hexarelin stimulates GH release in humans | Multiple human clinical studies (not large RCTs), including Anderson et al. 1993 and Ghigo et al. 1994 | Positive, robust | High |
| Hexarelin raises cortisol and ACTH in humans | Human clinical data, multiple studies | Positive (unwanted elevation) | High |
| Ipamorelin selectively stimulates GH without cortisol/prolactin in animals | Rat studies, Raun et al. 1998 | Positive for selectivity claim | Moderate (animal data, limited human confirmation) |
| Ipamorelin stimulates GH in humans | Limited human pharmacology data; Phase I data referenced in some reviews | Positive | Moderate |
| Hexarelin receptor desensitization with daily dosing | Human and animal studies showing blunted GH response over days to weeks | Negative (attenuation of effect) | Moderate to High |
| Body composition improvement in humans from either peptide | No published head-to-head human RCT; class-level GH secretagogue data only | Uncertain | Very Low |
| Hexarelin has cardioprotective effects via CD36 | Animal models and in vitro; Muccioli et al. and Broglio et al. publications | Positive in animal models | Low (no human RCT) |
| GHRH analog combination amplifies GH pulse for both peptides | Pharmacological synergy established in human studies for the secretagogue class | Positive synergy | Moderate |
How Do They Stimulate GH Release, With Specific Numbers?
Both peptides bind GHSR-1a, a G-protein coupled receptor highly expressed on pituitary somatotrophs and hypothalamic neurons. Binding activates Gq/11 signaling, raises intracellular IP3 and diacylglycerol, triggers calcium release from the endoplasmic reticulum, and drives GH vesicle exocytosis. They simultaneously suppress somatostatin tone via hypothalamic interneurons, which amplifies the net GH pulse.
In human studies, hexarelin at approximately 1 to 2 mcg/kg IV produced plasma GH peaks that were among the highest of any synthetic secretagogue tested at that time, with Ghigo et al. (1994, Journal of Clinical Endocrinology and Metabolism) reporting mean GH peaks in the range of 40 to 90 ng/mL depending on age and sex of subjects. These are directional figures from that paper; the reader should consult the original for exact means and confidence intervals.
Raun et al. (1998) showed in rat pituitary cell assays that ipamorelin had an EC50 in the low nanomolar range for GH release, comparable to GHRP-6, but crucially did not stimulate ACTH release even at supraphysiological concentrations, distinguishing it from hexarelin and GHRP-6 at the receptor pharmacology level.
What this mechanism does NOT prove: A larger acute GH pulse in a pharmacology study does not prove better long-term anabolic, lipolytic, or anti-aging outcomes in humans. GH pulse shape and IGF-1 response are what drive most downstream physiology, and neither peptide has published long-term human outcome data for body composition, strength, or longevity endpoints.
What Are the Real Side-Effect Differences?
This is the most clinically important distinction between the two compounds and the section most commodity pages underplay.
Hexarelin reliably elevates cortisol and ACTH in human subjects. This is not an idiosyncratic reaction; it is a pharmacological consequence of GHSR-1a activation on corticotroph cells and possibly hypothalamic CRH neurons. Elevated cortisol over time is catabolic, immunosuppressive, and metabolically unfavorable, which partially counteracts the anabolic intent of GH secretagogue use. Prolactin elevation has also been documented with hexarelin in human studies.
Ipamorelin, by contrast, showed no significant ACTH, cortisol, or prolactin elevation in the Raun et al. rat model at doses producing equivalent GH stimulation. The molecular basis appears to be the slightly different binding pose at GHSR-1a that avoids sufficient activation of the signaling branches coupling to ACTH release. Whether this selectivity fully holds across the dose range used in human research settings remains less certain because comprehensive human dose-escalation data for ipamorelin are not as publicly available as for hexarelin.
Water retention and transient hunger (ghrelin-like effect) are shared class effects of both peptides, expected from GHSR-1a agonism.
Does Hexarelin Cause Faster Receptor Desensitization?
Yes, and this is a practical protocol concern. Human studies administering hexarelin multiple times daily or daily over several weeks have documented a progressive blunting of the GH response, consistent with GHSR-1a downregulation and desensitization. This is one reason some clinical investigators trialed hexarelin specifically as a diagnostic tool rather than a chronic therapeutic.
Ipamorelin has less published human desensitization data. Animal infusion models do show blunting with continuous exposure, which is expected for any GPCR agonist. The clinical implication is that intermittent pulsatile dosing, rather than multiple daily injections, is the strategy most consistent with preserving receptor sensitivity for either compound.
What Most Comparison Pages Get Wrong
1. Treating "more GH" as an unqualified win for hexarelin. The cortisol and prolactin co-stimulation means the net hormonal environment from hexarelin is more complex than raw GH numbers suggest. Whether a larger GH pulse with concurrent cortisol elevation produces a better outcome than a smaller clean GH pulse from ipamorelin is not settled by any human trial.
2. Citing ipamorelin's selectivity as proven in humans. The selectivity data are primarily from Raun et al.'s rat work. Human pharmacology data for ipamorelin are less complete in the public literature than for hexarelin. The selectivity claim is well-grounded mechanistically and in animal models, but it should be labeled as such rather than stated as a confirmed human clinical fact.
3. Ignoring CD36 activity of hexarelin. Hexarelin binds CD36 independent of GHSR-1a. This has been studied in the context of cardiac protection and adipose tissue metabolism in animal models. It is not simply a "stronger ghrelin receptor agonist"; it has additional receptor biology that ipamorelin does not share. Whether this CD36 activity is beneficial, neutral, or harmful in the human context of unsupervised use is unknown.
4. Neglecting peptide purity sourcing reality. Neither peptide is manufactured under pharmaceutical GMP for the research supply chain in most cases. Third-party mass spectrometry and HPLC certificates of analysis should be the baseline verification step, not optional. Sequence accuracy does not guarantee absence of oxidized byproducts, residual solvents, or bacterial endotoxins from synthesis.
Honest Head-to-Head Comparison Table
| Property | Hexarelin | Ipamorelin | Winner / Note |
|---|---|---|---|
| Absolute GH pulse magnitude | Higher (human data) | Lower at equivalent dose | Hexarelin, but see cortisol caveat |
| Cortisol/ACTH co-stimulation | Yes, documented in humans | Minimal in animal models | Ipamorelin |
| Prolactin elevation | Yes, documented | Minimal in animal models | Ipamorelin |
| GHSR-1a selectivity | Lower (also binds CD36) | Higher | Ipamorelin |
| Human clinical data volume | More published studies | Fewer published human studies | Hexarelin for evidence depth |
| Receptor desensitization risk | Higher with daily dosing | Lower (animal data); less human data | Ipamorelin (tentatively) |
| Combination with GHRH analog | Synergistic; amplifies cortisol too | Synergistic; cleaner hormonal profile | Ipamorelin for combination protocols |
| FDA approval | None | None (compounded use only) | Neither |
| WADA status | Prohibited | Prohibited | Neither is safe for tested athletes |
| Body composition human RCT | None available | None available | Neither wins; both speculative |
Dosing and Operational Label Literacy
What human research used: Hexarelin human pharmacology studies used IV and subcutaneous doses roughly in the 1 to 2 mcg/kg range as single administrations for GH axis testing. These are not chronic therapeutic dose approvals. Ipamorelin human dose data in the public literature are limited; extrapolated protocols in research settings commonly cite 100 to 300 mcg per subcutaneous injection, typically once to three times daily, timed around sleep or fasting periods to align with natural GH pulse windows. These numbers come from compounding pharmacy protocols and researcher-practitioner consensus, not FDA-reviewed clinical trials.
Reading a COA for these peptides:
- Purity by HPLC should be reported as a percentage of the main peak area. Look for values above 98% for research-grade peptides. Values below 95% suggest meaningful impurity load.
- Mass spectrometry (ESI-MS or MALDI) should confirm the molecular weight matches the theoretical: hexarelin MW approximately 887 Da, ipamorelin MW approximately 711 Da.
- Endotoxin testing (LAL assay) is critical for injectables. A COA without endotoxin data is incomplete for any compound intended for subcutaneous use.
- Residual solvent panel and sterility testing are the next tier; these are often absent from research-grade COAs and represent a real sourcing gap.
Reconstitution math: A 2 mg vial of ipamorelin reconstituted with 2 mL bacteriostatic water yields 1 mg/mL (1000 mcg/mL). A 200 mcg dose requires 0.2 mL, drawn to the 20-unit mark on a U-100 insulin syringe. Always verify your concentration before drawing; dosing errors at 10-fold magnitude are the most common reconstitution mistake.
Stability and Formulation Gotchas
Both hexarelin and ipamorelin are supplied as lyophilized (freeze-dried) powder. The lyophilization process removes water to arrest hydrolysis, the primary degradation pathway. Once reconstituted, the peptide bonds become vulnerable again to aqueous hydrolysis, and oxidation of susceptible residues (tryptophan and methionine analogs in the sequence) begins.
Why bacteriostatic water and not sterile water for injection (SWFI): Bacteriostatic water contains 0.9% benzyl alcohol, which inhibits microbial growth over the multi-use period of a reconstituted vial. SWFI is sterile at opening but becomes a microbiological risk once punctured repeatedly. The benzyl alcohol does not affect peptide stability at the concentrations used.
Temperature sensitivity: Lyophilized vials are stable at room temperature for short periods during shipping but should be stored at 2 to 8 degrees Celsius long-term, and away from light. Freezing reconstituted peptide solutions is generally not recommended because freeze-thaw cycles promote aggregation and can introduce particulates.
What degradation looks like: Cloudiness, yellow or brown discoloration, or visible particulates in the reconstituted solution are discard signals. A properly reconstituted peptide solution should be clear and colorless to very faintly white. Any deviation from this warrants disposal rather than continued use.
The pH gotcha: Bacteriostatic water has a pH near 5.7. Most GH secretagogue peptides are stable in a mildly acidic environment. Mixing with alkaline diluents or co-injecting with compounds requiring basic pH can accelerate degradation. This is relevant when practitioners consider multi-peptide combination injections.
FAQ
What is the core difference between hexarelin and ipamorelin?
Hexarelin is a more potent GH secretagogue that also stimulates cortisol and prolactin release via CD36 and ghrelin-receptor pathways. Ipamorelin is selective for GH with minimal cortisol or prolactin spillover at standard doses, making it the lower-side-effect option despite producing a smaller absolute GH pulse.
Which peptide produces a larger GH pulse?
Hexarelin consistently produces larger GH pulses than ipamorelin at equivalent molar doses in human studies. Anderson et al. (1993) documented robust GH peaks with hexarelin in healthy adults. The trade-off is co-stimulation of cortisol and prolactin that ipamorelin largely avoids.
Does hexarelin raise cortisol?
Yes. Human clinical data show hexarelin increases plasma cortisol and ACTH alongside GH. This is a well-documented pharmacological effect, not a rare adverse event. Ipamorelin does not meaningfully raise cortisol at doses studied in animal and early human work.
Can you combine hexarelin or ipamorelin with a GHRH analog like CJC-1295?
Both peptides act at the ghrelin receptor (GHSR-1a) and synergize with GHRH analogs that act at the GHRH receptor. Combining either with a GHRH analog amplifies GH pulse magnitude. With hexarelin, the combination also amplifies cortisol and prolactin co-stimulation, a risk that is lower with ipamorelin.
How quickly does hexarelin cause receptor desensitization?
Repeated daily dosing of hexarelin produces measurable attenuation of GH response within days to weeks in human studies, attributable to GHSR-1a downregulation. Ipamorelin, used intermittently, shows less published evidence of rapid desensitization, though continuous infusion models in animals do show blunting.
What doses are used in human research?
Hexarelin human studies have used intravenous and subcutaneous doses roughly in the 1 to 2 mcg/kg range. Ipamorelin human pharmacology data are more limited; animal studies typically use 1 to 300 mcg/kg ranges, and extrapolated human protocols in research settings commonly cite 100 to 300 mcg per injection, though these are not FDA-approved doses.
Is either peptide FDA-approved?
Neither hexarelin nor ipamorelin is FDA-approved as a drug. Ipamorelin is an active ingredient in some compounded formulations. Hexarelin has no current approved clinical application in the United States. Both are research compounds outside of any approved compounded preparation.
How should these peptides be stored after reconstitution?
Both are lyophilized peptides that should be reconstituted with bacteriostatic water. After reconstitution, refrigeration at 2 to 8 degrees Celsius is required. Degradation is driven by hydrolysis and oxidation; reconstituted solutions are generally considered stable for roughly 4 weeks refrigerated, though formal stability data for these specific peptides are limited in the public literature.
Which is better for body composition?
There is no head-to-head human RCT comparing body composition outcomes for hexarelin versus ipamorelin. GH secretagogues as a class have shown modest lean mass and fat mass effects in short human trials, but neither peptide has an approved body composition indication. Extrapolating animal data to human outcomes is speculative.
What does a degraded peptide vial look like?
A degraded or contaminated vial may appear cloudy, show visible particulates, or have a yellow or brown discoloration versus a clear to faintly white lyophilized cake or clear solution. Any cloudiness after reconstitution with sterile water that does not clear on gentle swirling is a discard signal.
Are these peptides detectable on sports drug tests?
Both hexarelin and ipamorelin are prohibited by WADA under the category of peptide hormones, growth factors, and related substances. Urine and blood detection methods exist. Athletes subject to anti-doping rules should treat both as prohibited substances.
Sources
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561.
- Ghigo E, Arvat E, Rizzi G, et al. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man. Journal of Clinical Endocrinology and Metabolism. 1994;78(3):693-698.
- Broglio F, Gottero C, Prodam F, et al. Non-acylated ghrelin counteracts the metabolic but not the neuroendocrine response to acylated ghrelin in humans. Journal of Clinical Endocrinology and Metabolism. 2004;89(6):3062-3065.
- Muccioli G, Broglio F, Valetto MR, et al. Growth hormone-releasing peptides and the cardiovascular system. Annals of Endocrinology (Paris). 2000;61(1):27-31.
- Arvat E, Maccario M, Di Vito L, et al. Endocrine activities of ghrelin, a natural growth hormone secretagogue, in humans: comparison and interactions with hexarelin. Journal of Clinical Endocrinology and Metabolism. 2001;86(3):1169-1174.
- Deghenghi R, Cananzi MM, Torsello A, et al. GH-releasing activity of hexarelin, a new growth hormone releasing peptide, in infant and adult rats. Life Sciences. 1994;54(18):1321-1328.
- World Anti-Doping Agency. 2024 Prohibited List. WADA; 2024. Available at: https://www.wada-ama.org/en/prohibited-list
- Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977.
- Chapman IM, Bach MA, Van Cauter E, et al. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue in healthy elderly subjects. Journal of Clinical Endocrinology and Metabolism. 1996;81(12):4249-4257.